Medtronic (NYSE: MDT), Minneapolis, MN – FDA Inspections

Inspection records and compliance data for Medtronic in Minneapolis, Minnesota. 4 FDA inspections on record, last inspected February 01, 2016. Publicly traded as NYSE: MDT.

Company Profile

This profile covers Medtronic based in Minneapolis, Minnesota, United States.

FDA Inspection History

FDA inspections: 4
OAI: 0
VAI: 1
NAI: 3
Form 483s: 0
Warning letters: 0

First inspected January 22, 2010. Last inspected February 1, 2016.

Most cited issue areas

Availability of procedures1 inspection
Documentation elements for activities1 inspection

FDA inspections (4)

Date	Result	FDA center(s)	Insp. #
February 1, 2016	NAI	Biologics · Human Cellular, Tissue, and Gene Therapies	961416
February 5, 2014	NAI	Biologics · Human Cellular, Tissue, and Gene Therapies	864805
February 24, 2012	NAI	Biologics · Human Cellular, Tissue, and Gene Therapies	769018
January 22, 2010	VAI	Biologics · Human Cellular, Tissue, and Gene Therapies	642881

FDA documents

No Form 483s, Warning Letters or EIRs on record.

Related Companies (10)

Companies with similar regulatory profiles, compliance history, and operations.

Biomet North Central dba

Innovative Blood Resources, A Division of New York Blood Center, Inc. DBA Memorial Blood Centers

Octapharma Plasma Inc

Children's Hospital & Clinics of Minnesota

Lions Gift of Sight

CSL Plasma Inc.

Talecris Plasma Resources, Inc

St. Mary's Regional Health Center

Innovative Blood Resources, a Division of New York Blood Center, Inc. d.b.a. Memorial Blood Centers

M Health Fairview University of Minnesota Medical Center, East Bank-Blood Bank